Ushered three acquisition in the Healthcare and IT space.Acquisition of an Indian Institute of Science incubated leading PAC solutions company, to a canada based large PAC company.Exclusive Advisor for a $2Mn funding, to a leading Indian LMS/HIS company.Advisor to ETL (tender tiger)for a strategic acquisiiton of one of India's largest tender platform.Representing business interest of an upcoming 600 seater KPO .Looking to acquire a CPA firm in USA/EUROPE ticket size $5 to $15 Mn.Working closely with a AI/ML based Healthcare startup in stealth mode and raised seed.

Started by a Yale alumni, Eli was a healthcare buyout fund.Leading a team of 43 M&A professionals providing heavy loading & support for Several Acquisitions of USA based Ambulatory Surgical Centres for OpthamologyElectronic Healthcare Record and Patient EngagementCompanies providing RCM (Revenue Collection Management) Software's.Teletriage and Telehealth solutions.Acquisition of India's leading EHR company in the Opthamology space- Lekhisoft. Ivestment in a tele medicine company working to adress the Diabetes and Diabetic retinopathy malasie in India.Eli Global owns American Association of Professional coders , AAPC is the world's largest training and credentialing organization for the business of healthcare, with members worldwide working in medical coding , billing, auditing, compliance, clinical documentation improvement, revenue cycle management, and practice management.

BMA Capital was set up on the backdrop of sale of the BSE listed , LN Bangur owned APPM (Andhra Pradesh Paper Mills ltd ) to International Paper in 2011 for $312 Mn.Notable Transactions at BMA include: • March 11: Equity Infusement of $7.5 Mn by Tano Capital in the BSE listed JHS Sevendgaard labs (India’s largest FMCG contract manufacturing company) for a 14.66% stake. • December 11- Acquisition of Ordain Healthcare for $11 Mn by Chemo Espana (Ordain was a Chennai based pharmaceutical formulations marketing company present in high growth therapeutics segments of acute chronic and lifestyle diseases). • July 12: $5Mn PE infusement in Chatha Foods by Rajasthan Venture Capital Fund (Chatha is a frozen RTE meat manufacturer & largest Frozen Food supplier to Domino’s and Subway in India) • Feb 14: Sale of the Dalmia Continental owned Leonardo Brand of Olive Oils to Cargill India. • Executed the following exclusive mandates for growth equity infusement in • $7 Mn growth equity infusement mandate towards retail expansion of one of India’s largest frozen yoghurt chain. • $10 Mn infusement for one of India’s top 3 mattresses manufacturing companies wanting to foray in technical foams. • Funding for an IITK incubated cloud based cyber security & insider data theft prevention company. • Funding for an IITB incubated Nano Technology based Explosive Detectors. • Other funding mandates run include towards a leading Indian shoe/apparel brand • An oncology superspeciality company. • Leading Indian rehabilitation chain AktivOrtho in India. • A Leading Clinical Research Organization (CRO) based in Chennai ($6Mn) • A Meta search based Online Hotel Reservation Company.

Strategic Acquisitions and Joint Ventures for the BSE listed, Billion Dollar conglomerate Jubilant Lifesciences. (Now Jubilant Ingrevia) • Acquisition of Focus Brands Pvt. Ltd by Jubilant Enpro Pvt. Limited for $11 Mn. Focus Brands based out of Delhi was the Master Franchisee for leading liquor Brands. • Buy-out of Specialty Molecules Pvt. Ltd by Jubilant for US $ 5(Five) Mn.Speciality Molecules based out of Bombay was a manufacturer of Pyridine derivatives. • Acquisition of a 14% stake in Safe Foods (for $5Mn) manufacturer of several food preservatives including CPC (Cetyl Pyridium Chloride) using Pyridine as a raw material. • Part of the M&A and Finance and the business team which worked together to acquire Hollister Stier LLC for Jubilant ($180 Mn) thereby launching it into the sterile injectable’s segment. • Divestment of a 26% stake in Jubilant Beverages to Campari International for US$4 Mn approx. • Evaluated and assessed the acquisition of a company manufacturing Pyridine Derivatives with the Strategy of increasing Jubilant’ s business in China.Evaluated over 40 plus acquisitions in the healthcare space covering API manufacturing plants, Clinical Research Trial Companies , OTC brands, Speciality Chemicals ,Hospitals over the 6 year stint.Part of 4 annual strategy Meets which included Business Performance Reviews for the entirecompany covering all Business Units.Part of the divestment Initiatives of the Performace Chemicals group (erstwhile called "Vamicol") which was causing conglomerate discounting.